top of page

TBnet webinar January 2022

Writer's picture: majareimannmajareimann

Updated: Jan 24, 2022



Welcome to TBnet Webinar January 27 @16:00 CET!

TB vaccines will be in focus of two presentations:

  1. BCG vaccination to reduce the impact of COVID19?

  2. MTBVAC a new TB vaccine moving to efficacy trials 100 years after BCG.

Time: January 27, 2022 at16 PM (CET)

Meeting ID: 952 6624 6284

 

Speakers:


Cristina Prat, MD, PhD is medical Microbiologist holding a position in charge of Respiratory Tract Infection and Mycobacteria Section of the Department of Clinical Microbiology at Hospital Universitari Germans Trias i Pujol, Badalona/Barcelona, Spain.

Currently on leave from the clinical position at Institut Català de la Salut, she is working as scientific coordinator in several international projects in Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands. Research is focused in host pathogen interaction in bacterial and viral respiratory tract infections, staphylococcal infections and tuberculosis, aiming to bridge basics and clinical research.


Carlos Martin, MD, PhD. is Professor of Microbiology at the Faculty of Medicine at University of Zaragoza, Spain.

He is member of the Steering Committee of TBVI, with more than 30 years of experience in mycobacterial genetics and molecular epidemiology of TB. He and his team aim to develop novel TB vaccines and vaccination strategies to improve protection against pulmonary TB. Carlos Martin team designed and constructed MTBVAC, the first and only attenuated live M. tuberculosis vaccine in clinical trials. He has published more than 190 publications cited more than 9.700 times. Dr. Martin's research has been continuously funded by National and European Research Programs in TB research since 1992. Carlos Martin Team is part of CIBERES, a research network on respiratory diseases of the Spanish, Instituto de Salud Carlos III (ISCIII). His best hope is to accelerate the Phase 3 efficacy studies of MTBVAC in collaboration with Biofabri, the industrial partner of the University of Zaragoza, and with the support of TBVI European programs EDCTP and IAVI.


Panel:


Dr. Līga Kukša, Riga East University Hospital, Latvia

Prof. Martina Sester, Saarland University, Germany

Dr. Irina Kontsevaya, Research Center Borstel, Germany


Webinar chair:

Dr. Olena Rzhepishevska, Umeå University, Sweden



458 views0 comments

Recent Posts

See All

Comments


bottom of page